{"id":936936,"date":"2026-02-13T09:17:08","date_gmt":"2026-02-13T14:17:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/"},"modified":"2026-02-13T09:17:08","modified_gmt":"2026-02-13T14:17:08","slug":"vtv-therapeutics-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"vTv Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"
\n

HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin<\/em>, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences:<\/p>\n

\n Oppenheimer 36th Annual Healthcare Life Sciences Conference<\/strong>
\n
Date:\u00a0Thursday, February 26, 2026
Time: 11:20 AM ET
Format: Presentation Only
Location: Virtual
Webcast Link<\/a><\/p>\n

\n TD Cowen 46th Annual Health Care Conference<\/strong>
\n
Date:\u00a0Tuesday, March 3, 2026
Time: 9:50 AM ET
Format: Presentation and 1×1 Meetings
Location: Boston, MA
Webcast Link<\/a><\/p>\n

\n About<\/strong>\u00a0vTv<\/strong>\u00a0Therapeutics<\/strong>
vTv Therapeutics\u00a0is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv\u2019s clinical pipeline is led by\u00a0cadisegliatin<\/em>, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at\u00a0vtvtherapeutics.com<\/a>\u00a0or follow the company on\u00a0LinkedIn<\/a>\u00a0or\u00a0X<\/a>.<\/p>\n

\n About Cadisegliatin
<\/strong>
\n Cadisegliatin (TTP399)<\/em> is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin<\/em>, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin <\/em>has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).<\/p>\n

\n Cadisegliatin <\/em>is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.<\/p>\n

\n Investor Contact<\/strong>
\n
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com<\/a><\/p>\n

\n Media Contact<\/strong>
\n
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date:\u00a0Thursday, February 26, 2026Time: 11:20 AM ETFormat: Presentation OnlyLocation: VirtualWebcast Link TD Cowen 46th Annual Health Care Conference Date:\u00a0Tuesday, March 3, 2026Time: 9:50 AM ETFormat: Presentation and 1×1 MeetingsLocation: Boston, MAWebcast Link About\u00a0vTv\u00a0TherapeuticsvTv Therapeutics\u00a0is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. … <\/p>\n

Continue reading “vTv Therapeutics to Participate in Upcoming Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-936936","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nvTv Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"vTv Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date:\u00a0Thursday, February 26, 2026Time: 11:20 AM ETFormat: Presentation OnlyLocation: VirtualWebcast Link TD Cowen 46th Annual Health Care Conference Date:\u00a0Tuesday, March 3, 2026Time: 9:50 AM ETFormat: Presentation and 1×1 MeetingsLocation: Boston, MAWebcast Link About\u00a0vTv\u00a0TherapeuticsvTv Therapeutics\u00a0is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. … Continue reading "vTv Therapeutics to Participate in Upcoming Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T14:17:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzEzMiM3NDIxNDUzIzIwMTk3OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"vTv Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-02-13T14:17:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":320,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzEzMiM3NDIxNDUzIzIwMTk3OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"vTv Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzEzMiM3NDIxNDUzIzIwMTk3OTU=\",\"datePublished\":\"2026-02-13T14:17:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzEzMiM3NDIxNDUzIzIwMTk3OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MzEzMiM3NDIxNDUzIzIwMTk3OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"vTv Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"vTv Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"vTv Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date:\u00a0Thursday, February 26, 2026Time: 11:20 AM ETFormat: Presentation OnlyLocation: VirtualWebcast Link TD Cowen 46th Annual Health Care Conference Date:\u00a0Tuesday, March 3, 2026Time: 9:50 AM ETFormat: Presentation and 1×1 MeetingsLocation: Boston, MAWebcast Link About\u00a0vTv\u00a0TherapeuticsvTv Therapeutics\u00a0is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. … Continue reading \"vTv Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-13T14:17:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzEzMiM3NDIxNDUzIzIwMTk3OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"vTv Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2026-02-13T14:17:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/"},"wordCount":320,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzEzMiM3NDIxNDUzIzIwMTk3OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/","name":"vTv Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzEzMiM3NDIxNDUzIzIwMTk3OTU=","datePublished":"2026-02-13T14:17:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzEzMiM3NDIxNDUzIzIwMTk3OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MzEzMiM3NDIxNDUzIzIwMTk3OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vtv-therapeutics-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"vTv Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936936","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=936936"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936936\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=936936"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=936936"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=936936"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}